Crossmark

Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s12895-018-0071-3

Published Online: 2018-02-07

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Svendsen, Mathias Tiedemann https://orcid.org/0000-0002-4317-0873
Andersen, Flemming

Andersen, Kirsten Hammond

Andersen, Klaus Ejner
Funding

Funding for this research was provided by:

LEO Pharma
More Information

Article History

Received: 8 August 2017

Accepted: 30 January 2018

First Online: 7 February 2018

Ethics approval and consent to participate

: The trial has been approved by the Regional Committees on Health Research Ethics for Southern Denmark, Denmark (S-20160068G).Written consent has been obtained from all participants at the baseline visit, where all participants signed an informed consent form.

: Not applicable.

: KEA and MTS have received a grant from LEO® to conduct the trial. The EM and app are developed and owned by LEO®. FA and KHA have no conflicts of interests. the authors declare that theyhave no competing interests

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.